Angiogenesis inhibitors

A compound in accordance with formula Ia:

• or a pharmaceutically acceptable salt, hydrate or prodrug thereof,
• wherein
• X is N;
• R1 is C6-10 aryl, C3-10 heterocyclyl, or C5-10 heteroaryl, said aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra;
• R2 is H, or C1-6 alkyl;
• R3 is H, or C1-10 alkyl;
• R4 C6-10 aryl, said aryl, being optionally substituted with from one to three members selected from Ra;
• R5 is H, or C1-10 alkyl, said alkyl being optionally substituted with from one to three members selected from Ra;
• Ra is H, C1-10 alkyl, halogen, NO2, R, NHC1-6 alkylR9, OR, NR7R8, CN, C6-10 aryl, C5-10 heteroaryl or C3-10 heterocyclyl;
• R is H, C1-6 alkyl or C1-6 alkylR9;
• R9 is C6-10 aryl, C3-10 heterocyclyl, or C5-10 heteroaryl said aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra;
• and
• R7&R8 are independently H, C1-10 alkyl, C3-6 cycloalkyl, COR, C6-10 aryl, C3-10 heterocyclyl, or C5-10 heteroaryl, said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra or NR7R8 can be taken together to form a heterocyclic 5-10 membered saturated or unsaturated ring containing, in addition to the nitrogen atom, one to two additional heteroatoms selected from the group consisting of N, O and S.